| Literature DB >> 27102155 |
Ana Lustig1, Ivo Shterev2, Susan Geyer3, Alvin Shi1, Yiqun Hu4, Yukari Morishita4, Hiroko Nagamura4, Keiko Sasaki4, Mayumi Maki4, Ikue Hayashi5, Kyoji Furukawa6, Kengo Yoshida4, Junko Kajimura4, Seishi Kyoizumi4, Yoichiro Kusunoki4, Waka Ohishi7, Kei Nakachi4, Nan-Ping Weng1, Tomonori Hayashi4.
Abstract
Ionizing radiation (IR) is a major source of cellular damage and the immediate cellular response to IR has been well characterized. But the long-term impact of IR on cell function and its relationship with aging are not known. Here, we examined the IR effects on telomere length and other biomarkers 50 to 68 years post-exposure (two time points per person) in survivors of the atomic bombing at Hiroshima during WWII. We found that telomere length of leukocytes was inversely correlated with the dose of IR (p=0.008), and this effect was primarily found in survivors who were exposed at younger ages; specifically those <12 years old (p=0.0004). Although a dose-related retardation of telomere shortening with age was observed in the cross-sectional data, longitudinal follow-up after 11 years did not show IR exposure-related alteration of the rate of telomere shortening with age. In addition, IR diminished the associations between telomere length and selected aging biomarkers that were observed in survivors with no dose. These included uric acid metabolism, cytokines, and blood T cell counts. These findings showed long-lasting detrimental effects of IR on telomere length of leukocytes in both dose- and age-at-exposure dependent manner, and on alterations of biomarkers with aging.Entities:
Keywords: Gerotarget; Hiroshima; aging; ionizing radiation; leukocytes; telomeres
Mesh:
Substances:
Year: 2016 PMID: 27102155 PMCID: PMC5129908 DOI: 10.18632/oncotarget.8801
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Demographics of the study cohort by dose group
| Characteristic | No dose | Low dose | High dose | |
|---|---|---|---|---|
| (<5mGy) | (5-700mGy) | (>700mGy) | ||
| Gender | Total | Total | Total | |
| Female | 80 | 62 | 78 | 0.40 |
| Male | 77 | 61 | 57 | |
| Total | 157 | 123 | 135 | |
| Age at first visit | ||||
| <65 y.o. | 78 | 48 | 70 | 0.09 |
| >65 y.o | 79 | 75 | 65 | |
| Median | 65.15 | 67.95 | 63.64 | 0.16 |
| Range | 55.1-80.1 | 55.1-80.0 | 54.9-79.1 | |
| Age ATB | ||||
| <12 y.o. | 82 | 57 | 82 | 0.07 |
| ≥12 y.o. | 75 | 66 | 52 | |
| Median | 9.6 | 12.8 | 7.9 | 0.66 |
| Range | 0.2-23.8 | 0.2-23.6 | 0.2-23.6 | |
| Average year span between 2 visits | 11 | 11 | 10.9 | 0.66 |
| BM dose (mGy) | ||||
| Median | 229 | 1302 | ||
| Range | 5-694 | 701-3755 |
Figure 1Telomere length for all subjects by dose groups
A. Representative telomere measurement data by Southern blot. Lanes 1 and 2 are the first and second time points, respectively, from a subject who was aged 16 ATB, and similarly lanes 3 and 4 are from a subject who was aged 2 ATB. B. Boxplots of telomere length (averaged across both samples) for all subjects (healthy plus ill) by dose groups. The middle line reflects the median, the box length reflects the interquartile range (Interquartile range, IQR = 75th percentile − 25th percentile), and the whiskers reflect the 5th and 95th percentiles. Points represent specific values in the quantiles beyond the whiskers. Here, telomere lengths appear significantly shorter in those with increased dose groups (p for trend = 0.008). C. Boxplots of telomere length (averaged across both visits) for all subjects by subject age at the time of the bombing (age ATB < 12 vs. ≥ 12 years old) and by dose groups. An interaction effect is shown, where telomere lengths significantly differ between dose groups in those who were age < 12 vs. ≥ 12 years old ATB (p for trend = 0.0004), but no significant difference was observed across dose groups in those who were ≥ 12 years old ATB (p = 0.58).
Figure 2Telomere length change versus age in all study subjects
A. Scatterplot of telomere length versus age at blood collection for all subjects (healthy plus ill), and with data for both visits reflected (i.e. 2 points per subject). There is a significant interaction effect with differential relationships between telomere length and age for the different dose groups (p = 0.0067). B. Scatterplot of the average annual rate of change in telomere length between the first and second visits versus the age at the first visit for all subjects. There is no significant interaction effect to differentiate relationships between telomere length change and age by dose groups (p = 0.29). C. Boxplots of the average annual rate of telomere length change with age for all subjects by subject age at the time of the bombing (age ATB < 12 vs. ≥ 12 years old) and by dose groups. No interaction effects were detected for either age < 12 or ≥ 12 years old ATB (p for trend = 0.358 and 0.143, respectively).
Association of telomere length and biomarkers in healthy subjects
| Biomarker | No dose | Low dose | High dose | No-Hi | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | Co-efficient | Mean | Co-efficient | Mean | Co-efficient | |||||
| Creatinine (mg/dL) | 0.7 | 0.000 | −0.8 | 0.8 | 0.7 | 0.003 | −0.28 | |||
| Uric acid (mg/dL) | 5.2 | 0.000 | −0.1 | 5.1 | 5.4 | 0.053 | ||||
| C-reactive protein | 0.2 | 0.2 | 0.2 | 0.036 | −0.19 | |||||
| Albumin (mg/dL) | 4.5 | 0.005 | 0.4 | 4.4 | 4.4 | 0.020 | ||||
| HDL cholesterol (mg/dL) | 64.4 | 59.7 | 62.9 | 0.010 | 0.01 | |||||
| GCSF (pg/ml) | 48.2 | 0.021 | 0.0 | 50.8 | 0.024 | 0.0 | 48.4 | |||
| IFNG (pg/ml) | 296.9 | 0.021 | 0.0 | 273.1 | 0.024 | 0.0 | 316.5 | |||
| IL-7 (pg/ml) | 8.9 | 0.049 | 0.0 | 12.7 | 0.000 | 0.0 | 7.8 | |||
| IL-1B (pg/ml) | 3.4 | 0.021 | 0.0 | 2.6 | 2.9 | |||||
| IL-6 (pg/ml) | 13.3 | 0.034 | 0.0 | 9.9 | 20.2 | |||||
| TNF-α (pg/ml) | 175.7 | 0.034 | 0.0 | 95.8 | 240.5 | |||||
| IL-10 (pg/ml) | 9.9 | 8.7 | 0.001 | 0.0 | 15.1 | |||||
| IL-12.p70 (pg/ml) | 24.8 | 37.3 | 0.006 | 0.0 | 26.1 | |||||
| IL-13 (pg/ml) | 24.8 | 22.9 | 0.039 | 0.0 | 26.1 | |||||
| % of CD3+ T cells in lymphocyte | 67.0 | 0.000 | 0.0 | 66.6 | 64.9 | 0.008 | ||||
| % of CD4+ T cells in lymphocyte | 45.7 | 0.021 | 0.0 | 44.2 | 0.011 | 0.0 | 44.5 | |||
| % of CD4+CD45RA+(naïve) T cells in lymphocyte | 17.4 | 0.000 | 0.0 | 15.8 | 0.052 | 0.0 | 16.6 | |||
| Ratio of CD4+CD45Ra+ vs. CD4+CD45Ra- | 0.7 | 0.021 | 0.3 | 0.6 | 0.7 | |||||
| Ratio of CD4/CD8 | 3.8 | 3.4 | 0.052 | 0.0 | 3.7 | |||||
p-value was derived from a comparison of telomere length and biomarkers using GEE model adjusted with FDR.
p-value was derived from Wilcoxon test between no and high dose groups of the biomarkers.
Figure 3Comparison of telomere length and age at blood collection between healthy and ill subjects
A. Boxplots of telomere length for healthy vs. ill subjects separated by dose groups. The middle line reflects the median, the box length reflects the interquartile range (IQR = 75th percentile − 25th percentile), and the whiskers reflect the 5th and 95th percentiles. Points plotted beyond those lines reflect outliers. Here, a significant difference in the distribution of telomere lengths was only observed between healthy and ill subjects in those who were in the high dose group (p = 0.01). B. Scatterplots of telomere length versus age at blood collection for both visits by healthy vs. ill subjects and separated for each dose group. No significant difference in telomere length change with age between healthy and ill subjects was observed regardless of dose groups, based on the generalized estimating equation (GEE) models.